Osteoimmunology: Can We Prevent Bone Loss in Rheumatoid Arthritis with Modern Antirheumatic Drugs?
Calcified Tissue International · 11.04.2026 · 117 (1)
DOI: 10.1007/s00223-026-01504-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Calcified Tissue International, online erschienen am 11.04.2026. Verfasst von Hennie G Raterman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Northwest Clinics, Alkmaar, The Netherlands. hg.raterman@nwz.nl. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Bone Resorption, Osteoporosis. Die Arbeit nennt 139 Literaturangaben.
Abstract (Originalsprache)
In rheumatoid arthritis (RA), local and systemic inflammation and immobility lead to both generalized and local bone loss and an increased risk of fractures. Osteo-immunology, the shared mechanisms and crosstalk between immunology and bone has revealed insight in the pathogenesis: the upregulated inflammatory cytokines (TNFa, IL-1 and IL6) and, apart from that, anticitrullinated proteins antibodies (ACPA) stimulate the osteoclastogenesis with upregulated RANKL leading to increased bone resorption, while recent data also show an inhibited bone formation. Initially with the TNF blocker infliximab, and later with bDMARDS other biologics and even with combination of conventional DMARDs, generalized bone loss and erosions could be arrested. In the research agenda, lack of long-term data, fracture data and data on bone quality with HRpQCT was discussed, as well as exciting new data on erosion repair in studies with tocilizumab and baractinib. To summarize, the enormous developments both in the basic field of osteoimmunology combined with the introduction of powerful anti-inflammatory drugs in RA strongly prevents the local and generalized bone loss in RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Northwest Clinics, Alkmaar, The Netherlands. hg.raterman@nwz.nl.
- University of Verona, Verona, Italy.
- Facultad de Medicina UNAM, Clinical Epidemiology Unit Hospital Infantil de México Federico Gomez, Mexico City, Mexico.
- Sørlandet Hospital, Kristiansand, Norway.
- Hospital Aranda de La Parra, Leon, GTO, Mexico.
- Centro de Diagnostic de Osteoporosis y Enfermedades Reumaticas (CEDOR), Lima, Peru.
Zitieren
APA
Raterman, H. G., Adami, G., Clark, P., Haugeberg, G., Torres, J. M., Neira, L. V., Zakraoui, L., Zerbini, C., Messina, O. D., Lems, W. F., & IOF Osteoimmunology working group (2026). Osteoimmunology: Can We Prevent Bone Loss in Rheumatoid Arthritis with Modern Antirheumatic Drugs?. Calcified Tissue International, 117(1). https://doi.org/10.1007/s00223-026-01504-y
Vancouver
Raterman HG, Adami G, Clark P, Haugeberg G, Torres JM, Neira LV, et al. Osteoimmunology: Can We Prevent Bone Loss in Rheumatoid Arthritis with Modern Antirheumatic Drugs?. Calcified Tissue International. 2026;117(1). doi:10.1007/s00223-026-01504-y
BibTeX
@article{Raterman2026,
author = {Raterman, Hennie G and Adami, Giovanni and Clark, Patricia and Haugeberg, Glenn and Torres, Jorge Morales and Neira, Luis Vidal and Zakraoui, Leith and Zerbini, Cristiano and Messina, Osvaldo D and Lems, Willem F and IOF Osteoimmunology working group, IOF Osteoimmunology working group},
title = {Osteoimmunology: Can We Prevent Bone Loss in Rheumatoid Arthritis with Modern Antirheumatic Drugs?},
journal = {Calcified Tissue International},
year = {2026},
volume = {117},
number = {1},
doi = {10.1007/s00223-026-01504-y}
}
EUVIMED